

BEST AVAILABLE COPY

Serial No. 09/995,693

AMENDMENT TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS

Claims 1-50 (cancelled)

51. (New) A method of treating cancer in a mammal, comprising administering an effective amount of hepatocyte growth factor (HGF) receptor antagonist to the mammal, wherein said HGF receptor antagonist comprises a chimeric antibody, humanized antibody, human antibody, or fragment thereof.
52. (New) The method of Claim 51, wherein said cancer is selected from the group consisting of squamous cell carcinoma, small cell lung cancer, non-small cell lung cancer, gastrointestinal cancer, liver cancer, kidney cancer, pancreatic cancer, cervical cancer, bladder cancer, hepatoma, breast cancer, colon carcinoma, head and neck cancer, and combinations thereof presented in a single mammal.
53. (New) The method of claim 51, wherein said cancer is a carcinoma, lymphoma, sarcoma, blastoma or leukemia.
54. (New) The method of claim 51, wherein said cancer is accompanied by increased levels of HGF or overexpression or activation of HGF receptor in the mammal.
55. (New) The method of claim 51, wherein the antibody is a chimeric antibody.
56. (New) The method of claim 51, wherein the antibody is a humanized antibody.
57. (New) The method of claim 51, wherein the antibody is a human antibody.
58. (New) The method of claim 51, wherein said HGF receptor is the c-Met receptor.
59. (New) The method of claim 51, wherein said antagonist inhibits binding of human HGF to the c-Met receptor.

Serial No. 09/995,693

60. (New) The method of claim 51, wherein said antibody is a monoclonal antibody.
61. (New) The method of claim 51, wherein said antibody is a chimeric antibody.
62. (New) The method of claim 51, wherein said antibody is a humanized antibody.
63. (New) The method of claim 51, wherein said antibody is a human antibody.
64. (New) The method of claim 51, wherein said antibody is an antibody fragment.
65. (New) The method of claim 51, wherein said antibody binds to the same epitope as the epitope to which a Fab fragment of the monoclonal antibody produced by the hybridoma cell line deposited under American Type Culture Collection Accession Number ATCC HB-11894 binds.
66. (New) The method of claim 51, wherein said antibody binds to the same epitope as the epitope to which a Fab fragment of the monoclonal antibody produced by the hybridoma cell line deposited under American Type Culture Collection Accession Number ATCC HB-11895 binds.
67. (New) The method of claim 51, wherein said antibody has binding ability of a Fab fragment of the monoclonal antibody produced by the hybridoma cell line deposited under American Type Culture Collection Accession Number ATCC HB-11894 binds.
68. (New) The method of claim 51, wherein said antibody has binding ability of a Fab fragment of the monoclonal antibody produced by the hybridoma cell line deposited under American Type Culture Collection Accession Number ATCC HB-11895 binds.
69. (New) The method of claim 51, wherein said antibody competes with the monoclonal antibody produced by the hybridoma cell line deposited under American Type Culture Collection Accession Number ATCC HB-11894 for binding to HGF receptor.
70. (New) The method of claim 51, wherein said antibody competes with the monoclonal antibody produced by the hybridoma cell line deposited under American Type Culture Collection Accession Number ATCC HB-11895 for binding to HGF receptor.